Printer Friendly

Printed from

HIV Drugs Market in India 2010-2014

TechNavio’s analysts forecast the HIV Drugs market in India to reach US$54 million by 2014. One of the key factors contributing to this market growth is the increasing prevalence of HIV in India and the longer life expectancy of HIV patients. The HIV Drugs market in India has also been witnessing the development of immune-based therapies for HIV. However, the inadequate availability of physicians with a specialization in HIV treatment could be a challenge to the growth of this market. TechNavio’s report, HIV Drugs Market in India 2010–2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on India and covers healthcare institutions, over the counter/retail, and HIV rehabilitation centers. The report analyzes the current HIV Drugs market landscape and its growth prospects. It also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market include Cipla Ltd., Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., and Zydus Cadila Healthcare Ltd.

Key questions answered in this report:
What will the market size be in 2014 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?

01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Cipla Limited
11.2 Hetero Drugs Ltd
11.3 Ranbaxy Laboratories Ltd.
11.4 Zydus Cadila Healthcare Ltd
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: HIV Drugs Market in India 2010–2014 (US$ million)
Exhibit 2: India HIV Drugs Market Segmentation by Geography – 2010
Exhibit 3: Split of Key Customer Segments in the HIV Drugs Market in India – 2010
Exhibit 4: Price Range of HIV Drugs for Treatments in India
Exhibit 5: Split of Modes of HIV Disease Transmissions in India
Exhibit 6: Split of Indian Companies and MNC on India HIV Drugs Market – 2010
Exhibit 7: HIV Drugs Market in India by Key Vendor Segmentation – 2010
Increased Life Expectancy Driving Use of HIV Drugs in India

TechNavio, a market research leader in the area of Healthcare, recently published its report, HIV Drugs Market in India 2010–2014. The report focuses exclusively on the Indian market and discusses significant trends impacting growth. The report is based on an in-depth study of the market with inputs from key industry participants. In addition to profiling key vendors, the report discusses the important drivers, trends, and challenges for the industry.

TechNavio’s report highlights that Indian HIV drug manufacturers have enjoyed good growth rates because of the privatization of healthcare industries; institutions such as hospitals and clinics are able to provide high-quality facilities at optimum costs . Increasingly, these private healthcare facilities have also begun to implement their own Anti-Retroviral (ARV) programs, enrolling a number of HIV patients and increasing access to treatment at reduced cost.

Commenting on the report, an analyst from TechNavio’s Healthcare team said, “The increased life expectancy of patients has a direct correlation with the amount of HIV drugs consumed. With strong support from social organizations, vendors are ensuring that their products reach almost every part of the globe. Regions such as Andhra Pradesh, Maharashtra, Karnataka, Nagaland, Goa, and Tamil Nadu are expected to boost the revenues of HIV Drugs market in India. This driver is expected to have a medium impact in the long term.”

Key findings from the report:
- HIV Treatment Procedures not 100 Percent Effective
- Lack of Available Physicians with Specialization in HIV Treatment
- High Cost of HIV Treatment

Companies Mentioned
Cipla Ltd., Hetero Drugs Ltd., Ranbaxy Laboratories Ltd. and Zydus Cadila Healthcare Ltd
Order Online - visit

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,

Page 1 of 2
Printed Dec 21, 2014
4:17:35 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email

Order information

Please verify that the product information is correct and select the format you require.

Product name

HIV Drugs Market in India 2010-2014

Web Address

Office Code



Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 1,500
Electronic (PDF) - Enterprisewide USD 2,500
Electronic (PDF) - 1 - 5 Users USD 1,800

Contact information

Please enter all the information below in block capitals.

Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Postal / Zip Code:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Dec 21, 2014
4:17:35 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card


Cardholder's Name:
Cardholder's Signature:
Expiry Date:
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
Sort Code:
Swift Code:
IBAN Number:
Bank Address:
Ulster Bank,
27-35 Main Street
Co. Dublin

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)